Bylvay (odevixibat) – which Ipsen acquired when it took over US biotech Albireo in a $952 million deal in 2023 – was being ...
Sanofi has retreated from a plan to file its anti-OX40L antibody amlitelimab for approval as a treatment for atopic ...
In transfusion medicine, “wrong blood in tube” is not simply a paperwork issue: a misidentified blood group can lead to a ...
Against the advice of FDA staff scientists, an advisory committee has narrowly voted in support of looser restrictions on ...
In the phase 3 MonumenTAL-6 trial, Tecvayli (teclistamab) and Talvey (talquetamab) cut the risk of disease progression or death by 89% compared to standard-of-care combinations used as second- to ...
The FDA has named Dexcom as the first medical device manufacturer that will take part in a pilot programme that could make it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results